01. Biblio B Cell CD22 11/21/2011

Biblio B Cell CD22 11/21/2011

 

1. Tedder T, Poe J, Haas K. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol 2005: 1-50.
 

2. Kawasaki N, Rademacher C, Paulson J. CD22 regulates adaptive and innate immune response of B cells. J Innate Immun 2011; 4: 411-9.

3. Raponi S, De Propris M, Intoppa S, Milani M, Vitale A, Elia L, Perbellini O, Pizzolo G, Goa R, Guarini A. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011; 6: 1098107.

4. Poe J, Hasegawa M, Tedder T. CD19, C21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Int Rev Immunol 2001; 6: 73962.

5. Bobbitt K, Justement L. Regulation of MHC class II signal transduction by the B cell co-receptors CD19 and CD22. J Immunol 2000; 10: 5588-96.

6. Mills D, Stolpa J, Cambier J. Cognate B cell signaling via MHC class II: differential regulation of B cell antigen receptor and MHC class II/lg-alpha beta signaling by CD22. J Immunol 2004; 1: 195-201.

7. Kedmi M, Bar-Shira A, Gurevich T, Giladi N, Orr-Urtreger A. Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease. Mol Neurodegener 2011; 6-66.

8. Chen W, Sigal D, Saven A, Paulson J. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leuk Lymphona 2011; (Epub ahead of print)

9. Dobbs A, Bosompem A, Coustan-Smith E, Tyerman G, Saulsbury F, Conley M. Agammaglobulinemia associated with BCR-B cells and enhanced expression of CD19. Blood 2011; 7: 1828-37.

10. Seite J, Guerrier T, Cornec D, Jamin C, Youinou P, Hillion S. TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. J Autoimmun 2011; 3: 190-7.

11. Jandus C, Simon H, von Gunten S. Targeting siglecs--a novel pharmacological strategy for immuno- and glycotherapy. Biochem Pharmacol 2011; 4: 323-32.

12. CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. J Immunol 20111; 3: 1554-63.

13. Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev 2009; 1: 128-43.

14. Walker J, Smith K. CD22: an inhibitory enigma. Immunology 2008; 3: 314-25.

15. Tedder T, Poe J, Haas K. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005; 88: 1-50.

16. Tedder T, Tuscano J, Sato S, Kehl J. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997; 15: 481-504.

17. Courtney A, Puffer E, Pontrello J, Yang Z, Kiessling L. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation. Proc Natl Acad Sci U S A 2009; 8: 25005-5.

18. Ghosh S, Bandulet C, Nitschke L. Regulation of B cell development and B cell signaling by CD22 and its ligands alpha2, 6-linked sialic acids. Int Immunol 2006; 4: Epub 2006 Feb 23.

 

19. Collins B, Smith B, Bengtson P, Paulson J. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol 2006; 2: 199-206.

20. Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev 2009; 1: 128-43.

21. Jellusova J, Wellmann U, Amann K, Winkler T, Nitschke L. CD22 x Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity. J Immunol 2010; 7: 3618-27.

22. Santos L, Draves K, Boton M, Grewal P, Marth J, Clark E. Dendritic celldependent inhibition of B cell proliferation requires CD22. J Immunol 2008; 7: 4561-9.

23. Nakashima H, Hamaguchi Y, Watanabe R, Ishiura N, Kuwano Y, Okochi H, Takahashi Y, Tamaki K, Sato S, Tedder T, Fujimoto M. CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions. J Immunol 2010; 9: 4637-45.

24. O'Reilly M, Paulson J. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 2009; 5: 240-8.

25. Griffiths M, Neal J, Fontaine M, Das T, Gasque P. Complement factor H, a marker of self protects against experimental autoimmune encephalomyelitis. J Immunol 2009; 7: 4368-77. J Immunol 2009; 7: 4368-77.

 

*END*